Heated, humidified air for the common cold

Singh, Meenu; Singh, Mandeep

doi:10.1002/14651858.cd001728.pub5

Cited by 28 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The evidence that vitamin C supplementation or probiotics used for prevention of the common cold, and zinc used for treatment of the common cold, are effective (Hao 2011; Hemilä 2013; Singh 2013a) is stronger than the evidence for Echiacea . Evidence for the effects of other CAM interventions is similarly limited ( Pelargonium sidoides , Timmer 2009) or even weaker (saline nasal irrigation, Kassel 2010; increased fluid intake Guppy 2011; heated humidified air, Singh 2013b; garlic, Lissiman 2012; and Chinese medical herbs, Zhang 2010). …”

Section: Discussionmentioning

confidence: 99%

Echinacea for preventing and treating the common cold

Karsch‐Völk

Barrett

Kiefer

et al. 2014

Cochrane Database of Systematic Reviews

200

View full text Add to dashboard Cite

BackgroundEchinacea plant preparations (family Asteraceae) are widely used in Europe and North America for common colds. Most consumers and physicians are not aware that products available under the term Echinacea differ appreciably in their composition, mainly due to the use of variable plant material, extraction methods and the addition of other components. ObjectivesTo assess whether there is evidence that Echinacea preparations are effective and safe compared to placebo in the prevention and treatment of the common cold.

show abstract

Section: Discussionmentioning

confidence: 99%

Echinacea for preventing and treating the common cold

Karsch‐Völk

Barrett

Kiefer

et al. 2014

Cochrane Database of Systematic Reviews

200

View full text Add to dashboard Cite

show abstract

“…Многочисленными исследованиями доказано, что ацетилцистеин уменьшает адгезию патогенных бактерий к эпителиальным клеткам слизистой оболочки дыхательных путей, вследствие этого снижается колонизация дыхательных путей патогенными микроорганизмами [25][26][27][28]. Кроме того, ацетилцистеин приводит к уменьшению образования биопленок грамположительными и грамотрицательными бактериями и грибами, а также уменьшает продукцию экстрацеллюлярного полисахаридного матрикса, что способствует разрушению зрелых биопленок [27][28][29].…”

Section: медикаментозное лечениеunclassified

Postnasal Drip Syndrome in Children. Recommendations

Kulagina¹

2019

View full text Add to dashboard Cite

Цель обзора: анализ современных возможностей терапии кашля у детей с синдромом постназального затекания слизи (СПНЗ) в клинической практике. Основные положения. У пациентов с острыми респираторными инфекциями и хроническими заболеваниями респираторного тракта важно как можно быстрее разжижать и выводить мокроту. Препаратами выбора для терапии кашля у детей, в том числе при СПНЗ, являются муколитики. Ацетилцистеин не подавляет местную иммунную защиту и не нарушает синтез секреторного иммуноглобулина А и лизоцима, оказывает антиоксидантное действие и, будучи предшественником глутатиона, способен уменьшать воспаление слизистой оболочки дыхательных путей и защищать ее от повреждающего действия свободных радикалов. Заключение. Препараты выбора при СПНЗ-муколитики. Ацетилцистеин является мукоактивным препаратом комплексного действия с благоприятным профилем безопасности, хорошо изученным в ходе многочисленных клинических международных и российских исследований. Ключевые слова: кашель, острые респираторные инфекции, постназальное затекание слизи, мукоактивный препарат.

show abstract

“…A Cochrane Review assessed that the current evidence could not support or refute effectiveness and recommended that there is a need for robustly designed and adequately powered randomised controlled trials (RCTs) to assess the effectiveness of rhinothermy to treat the common cold. 21 We have reported a tolerability study that found that a high flow nasal cannula device (myAIRVO 2, Fisher & Paykel Healthcare, Auckland, New Zealand) modified to deliver high flow humidified air at 41°C via wide bore nasal cannulae was well tolerated in healthy volunteers. 26 The potential advantage of this device for rhinothermy is that it can deliver a consistent temperature, humidity and flow rate direct into the upper airways.…”

Section: Open Accessmentioning

confidence: 99%

Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study

et al. 2018

View full text Add to dashboard Cite

ObjectiveTo determine the feasibility of a randomised controlled trial (RCT) of rhinothermy for the common cold.DesignOpen label, randomised, controlled feasibility study.SettingSingle-centre research institute in New Zealand recruiting participants from the community.Participants30 adult participants with symptoms of a common cold, presenting within 48 hours of the onset of symptoms.InterventionsParticipants were randomly assigned 2:1 to receive either 35 L/min of 100% humidified air at 41°C via high flow nasal cannulae, 2 hours per day for up to 5 days (rhinothermy), or vitamin C 250 mg daily for 5 days (control).Primary and secondary outcome measuresThe primary outcome was the proportion of screened candidates who were randomised. Secondary outcomes included: proportion of randomised participants who completed the study; modified Jackson scores from randomisation to 10 days after initiation of randomised regimen; time until feeling ‘a lot better’ compared with study entry; time until resolution of symptoms or symptom score at 10 days postrandomisation; proportion of organisms identified by PCR analysis of nasal swabs taken at baseline; the patterns of use of the rhinothermy device; estimated adherence of the control group; and rhinothermy device tolerability.ResultsIn all 30/79 (38%, 95% CI 27% to 50%) of potential participants screened for eligibility were randomised. Rhinothermy was well tolerated, and all randomised participants completed the study (100%, 95% CI 88% to 100%). The reduction from baseline in the modified Jackson score was greater with rhinothermy compared with control at days 2, 3, 4, 5 and 6, with the maximum difference at day 4 (−6.4, 95% CI −9.4 to −3.3). The substantial clinical benefit threshold for modified Jackson score was a 5-unit change.ConclusionsThis study shows that an RCT of rhinothermy compared with low-dose vitamin C in the treatment of the common cold is feasible.Trial registration numberACTRN12616000470493; Results.

show abstract

Heated, humidified air for the common cold

Cited by 28 publications

References 23 publications

Echinacea for preventing and treating the common cold

Echinacea for preventing and treating the common cold

Postnasal Drip Syndrome in Children. Recommendations

Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study

Contact Info

Product

Resources

About